Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis

Table 1 Baseline WPAI scores: RAJ3

WPAI domain^a	Placebo (N=101)	Peficitinib 100 mg (N=104)	Peficitinib 150 mg (N=102)	Peficitinib 100 mg + 150 mg (N=206)	p value^b
Absenteeism^c
n	50	60	53	113	0.385
Mean (SD)	4.29 (11.10)	7.61 (22.79)	9.52 (21.17)	8.50 (21.97)	0.385
Presenteeism^c
n	50	57	53	110	0.639
Mean (SD)	47.00 (28.94)	41.58 (28.83)	44.53 (31.04)	43.00 (29.82)	0.639
Loss of work productivity^c
n	50	57	53	110	0.529
Mean (SD)	48.89 (28.89)	42.57 (29.46)	47.19 (31.85)	44.80 (30.58)	0.529
Daily activity impairment
n	100	103	102	205	0.543
Mean (SD)	55.90 (28.92)	51.75 (28.26)	55.20 (28.97)	53.46 (28.60)	0.543

SD Standard deviation, WPAI Work Productivity and Activity Impairment
^aHigher WPAI scores indicate greater work/activity impairment, expressed as percentage
^bp values calculated using analysis of covariance, with no adjustment made for multiplicity
^cOnly “full-time paid workers” and “part-time paid workers” were included (not “homemakers”)

ISSN: 1478-6362